We have created IOTA as a resource to support the emerging areas of fragment-based drug discovery, structure-based drug design, high-content drug screening and lead optimization, key areas of modern drug discovery.

On this page we summarise our key publications and place them in the context of emerging science covering IOTA’s core interests of cancer and infectious disease.

A paper by Genentech scientists Dr John Moffat and Dr Joachim Rudolph and the IOTA scientist Dr David Bailey, describing the emerging relationships between target-based drug discovery and phenotypic drug discovery in cancer research